Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Way Crossover Study to Investigate the Bioequivalence of Entrectinib Polymorph Forms A and C Under Fasted Conditions in Healthy Subjects

Next Previous
Search
Trial Profile

A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Way Crossover Study to Investigate the Bioequivalence of Entrectinib Polymorph Forms A and C Under Fasted Conditions in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Acute myeloid leukaemia; Brain metastases; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors Genentech

    • Most Recent Events

    • 18 Jan 2021 Results from NCT02097810 ,NCT03796260 and NCT03796013 in patients and healthy subjects assessing pharmacokinetics and disposition of entrectinib,pharmacokinetics and disposition of entrectinib,published in the Investigational New Drugs
    • 21 Feb 2019 Status changed from recruiting to completed.
    • 14 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top